Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:. Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days. S...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2023-04-01
|
| Series: | Critical Care Explorations |
| Online Access: | http://journals.lww.com/10.1097/CCE.0000000000000890 |
| _version_ | 1797840210974736384 |
|---|---|
| author | Constantine J. Karvellas, MD Ram Subramanian, MD Jody C. Olson, MD Khurram Jamil, MD |
| author_facet | Constantine J. Karvellas, MD Ram Subramanian, MD Jody C. Olson, MD Khurram Jamil, MD |
| author_sort | Constantine J. Karvellas, MD |
| collection | DOAJ |
| description | IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting.
DESIGN:. Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days.
SETTING:. A retrospective analysis of data from the phase III CONFIRM study.
PARTICIPANTS:. Adult patients with HRS-AKI admitted to the ICU.
MAIN OUTCOMES AND MEASURES:. In this substudy, we evaluated outcomes of the ICU stay and the need for organ support, including renal replacement therapy (RRT).
RESULTS:. Among 300 patients with HRS-AKI from the CONFIRM study, 45 were treated in the ICU (terlipressin, 31/199 [16%]; placebo, 14/101 [14%]). On ICU admission, baseline demographics were similar across treatment arms, including severity of liver dysfunction. Among patients alive at the end of the ICU stay, those randomized to terlipressin had a significantly shorter median length of ICU stay than placebo (4 vs 11 d; p < 0.001). Terlipressin-treated patients had a significantly larger improvement in renal function from baseline versus placebo (–0.7 vs +0.2 mg/dL; p = 0.001), including when accounting for the interaction between treatment and day-of-patient-admission to the ICU (–0.7 vs +0.9 mg/dL; p < 0.001). Cumulative requirement for RRT through day 90 was improved in the terlipressin arm versus placebo (10/31 [32%] vs 8/14 [57%]; p = 0.12), although not significantly. Of 13 patients who received a liver transplant, five out of five (100%) in the placebo arm needed RRT through day 90 versus five out of eight (63%) in the terlipressin arm.
CONCLUSIONS:. In this subanalysis of CONFIRM, patients admitted to the ICU with HRS-AKI who received terlipressin were more likely to achieve renal function improvement, based on serum creatinine changes by the end of treatment, and had significantly shorter lengths of ICU stay than patients randomized to the placebo arm. |
| first_indexed | 2024-04-09T16:11:13Z |
| format | Article |
| id | doaj.art-7446f507db0848c2a43ddc054b4f3c16 |
| institution | Directory Open Access Journal |
| issn | 2639-8028 |
| language | English |
| last_indexed | 2024-04-09T16:11:13Z |
| publishDate | 2023-04-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Critical Care Explorations |
| spelling | doaj.art-7446f507db0848c2a43ddc054b4f3c162023-04-24T10:02:28ZengWolters KluwerCritical Care Explorations2639-80282023-04-0154e089010.1097/CCE.0000000000000890202304000-00008Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM TrialConstantine J. Karvellas, MD0Ram Subramanian, MD1Jody C. Olson, MD2Khurram Jamil, MD31 Department of Critical Care Medicine and Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, AB, Canada.2 Departments of Critical Care Medicine and Hepatology, Emory University, Atlanta, GA.3 Departments of Medicine and Surgery, University of Kansas Medical Center, Kansas City, KS.4 Mallinckrodt Pharmaceuticals, Hampton, NJ.IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:. Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days. SETTING:. A retrospective analysis of data from the phase III CONFIRM study. PARTICIPANTS:. Adult patients with HRS-AKI admitted to the ICU. MAIN OUTCOMES AND MEASURES:. In this substudy, we evaluated outcomes of the ICU stay and the need for organ support, including renal replacement therapy (RRT). RESULTS:. Among 300 patients with HRS-AKI from the CONFIRM study, 45 were treated in the ICU (terlipressin, 31/199 [16%]; placebo, 14/101 [14%]). On ICU admission, baseline demographics were similar across treatment arms, including severity of liver dysfunction. Among patients alive at the end of the ICU stay, those randomized to terlipressin had a significantly shorter median length of ICU stay than placebo (4 vs 11 d; p < 0.001). Terlipressin-treated patients had a significantly larger improvement in renal function from baseline versus placebo (–0.7 vs +0.2 mg/dL; p = 0.001), including when accounting for the interaction between treatment and day-of-patient-admission to the ICU (–0.7 vs +0.9 mg/dL; p < 0.001). Cumulative requirement for RRT through day 90 was improved in the terlipressin arm versus placebo (10/31 [32%] vs 8/14 [57%]; p = 0.12), although not significantly. Of 13 patients who received a liver transplant, five out of five (100%) in the placebo arm needed RRT through day 90 versus five out of eight (63%) in the terlipressin arm. CONCLUSIONS:. In this subanalysis of CONFIRM, patients admitted to the ICU with HRS-AKI who received terlipressin were more likely to achieve renal function improvement, based on serum creatinine changes by the end of treatment, and had significantly shorter lengths of ICU stay than patients randomized to the placebo arm.http://journals.lww.com/10.1097/CCE.0000000000000890 |
| spellingShingle | Constantine J. Karvellas, MD Ram Subramanian, MD Jody C. Olson, MD Khurram Jamil, MD Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial Critical Care Explorations |
| title | Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial |
| title_full | Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial |
| title_fullStr | Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial |
| title_full_unstemmed | Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial |
| title_short | Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial |
| title_sort | role of terlipressin in patients with hepatorenal syndrome acute kidney injury admitted to the icu a substudy of the confirm trial |
| url | http://journals.lww.com/10.1097/CCE.0000000000000890 |
| work_keys_str_mv | AT constantinejkarvellasmd roleofterlipressininpatientswithhepatorenalsyndromeacutekidneyinjuryadmittedtotheicuasubstudyoftheconfirmtrial AT ramsubramanianmd roleofterlipressininpatientswithhepatorenalsyndromeacutekidneyinjuryadmittedtotheicuasubstudyoftheconfirmtrial AT jodycolsonmd roleofterlipressininpatientswithhepatorenalsyndromeacutekidneyinjuryadmittedtotheicuasubstudyoftheconfirmtrial AT khurramjamilmd roleofterlipressininpatientswithhepatorenalsyndromeacutekidneyinjuryadmittedtotheicuasubstudyoftheconfirmtrial |